AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The medicine was well tolerated, with no unexpected safety issue
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Subscribe To Our Newsletter & Stay Updated